|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Stahler, Arndt; Heinemann, Volker; Neumann, Jens; Crispin, Alexander; Schalhorn, Andreas; Stintzing, Sebastian; Giessen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Vehling-Kaiser, Ursula; Stauch, Martina; Quietzsch, Detlef; Holch, Julian W.; Kruger, Stephan; Haas, Michael; Michl, Marlies; Einem, Jobst von; Kirchner, Thomas; Jung, Andreas und Modest, Dominik P.
(2017):
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
In: Anti-cancer drugs, Bd. 28, Nr. 7: S. 717-722
[PDF, 422kB]
Haas, Michael; Ormanns, Steffen; Bächmann, Sibylle; Remold, Anna; Krüger, Stephan; Westphalen, Christoph B.; Siveke, Jens T.; Wenzel, Patrick; Schlitter, Anna Melissa; Esposito, Irene; Quietzsch, Detlef; Clemens, Michael R.; Kettner, Erika; Laubender, Rüdiger P.; Jung, Andreas; Kirchner, Thomas; Böck, Stefan und Heinemann, Volker
(2017):
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
In: British Journal of Cancer, Bd. 116, Nr. 11: S. 1462-1469
Ormanns, Steffen; Haas, Michael; Baechmann, Sibylle; Altendorf-Hofmann, Annelore; Remold, Anna; Quietzsch, Detlef; Clemens, Michael R.; Bentz, Martin; Geissler, Michael; Lambertz, Helmut; Kruger, Stephan; Kirchner, Thomas; Heinemann, Volker und Boeck, Stefan
(2016):
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
In: British Journal of Cancer, Bd. 115, Nr. 12: S. 1520-1529
Modest, Dominik P.; Schulz, Christoph; Fischer von Weikersthal, Ludwig; Quietzsch, Detlef; Einem, J. C. von; Schalhorn, Andreas; Vehling-Kaiser, Ursula; Laubender, Rüdiger P.; Giessen, Clemens; Stintzing, Sebastian und Heinemann, Volker
(2014):
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
In: Anticancer Drugs, Bd. 25, Nr. 2: S. 212-218
[PDF, 442kB]